ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2410

Serious Infection Risk in Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Rheumatic Diseases: A US National Cohort Study

Bella Y. Mehta1, Sofia Pedro2, Gulsen Ozen3 and Kaleb Michaud4, 1Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 4University of Nebraska Medical Center, Omaha, NE

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Epidemiologic methods, fungal infections, Infection, opportunistic infections and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Session Title: Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Serious infections (SI) in patients with rheumatoid arthritis (RA) are a perpetual concern. We compared the risk by first and recurrent SIs in patients with RA compared to those with non-inflammatory rheumatic diseases (NIRD) in a real-world setting.

Methods: Participants had RA or NIRD from1998 through 2016 in the National Data Bank for Rheumatic Diseases (NDB). NIRD included diagnoses such as osteoarthritis, back pain syndromes, tendonitis, etc; this comparator group helps minimize selection and reporting bias. SIs were defined as those requiring hospitalization or intravenous antibiotics, or leading to death. All SIs were described by etiology and location and were additionally categorized as opportunistic or herpes zoster when they occur. Survival analysis methods (Cox regression, time to first infection using time-varying covariates and Andersen-Gill multiple failures model) were applied, both in a univariate and multivariable manner. Confounders included demographics, comorbidities, disease severity measures and glucocorticoid (GC) use.

Results: There were 20,361 RA and 6,176 NIRD patients who contributed to 81,499 and 20,665 patient-years of exposure, having had 1,643 (7.9%) and 281 (4.5%) SIs, respectively. A higher proportion of RA patients with SI were younger, had worse HAQ scores, lower BMI, and a higher frequency of GC use and smoking compared to NIRD patients (Table 1). The most frequent SIs by etiology were bacterial and by location was respiratory in both groups. The incidence rate ratios (IRR) of the first and recurrent SIs for RA vs. NIRD were similar (1.5 [1.3 -1.7]). The IRRs for opportunistic infections and herpes zoster ranged between 2.2 – 3.3. The multivariable analysis showed a significant SI risk increase in RA patients compared to NIRD (HR 1.32 [1.15-1.52]). By etiology, the risk of bacterial infections was significantly higher in patients with RA than NIRD. Respiratory, bloodstream infections with sepsis, skin, bone and joint infections were also significantly increased in RA (Table 2).

Conclusion: The risk of SIs, particularly bacterial, respiratory, blood stream, skin and joint infections is increased in RA patients compared to NIRD patients. The increased risk could be explained by immune dysregulation caused by the disease itself, comorbid conditions or medications. A limitation of this study is that there was a significant proportion of SIs that were not categorized by type or location in medical records. Further studies collecting detailed SI information and the impact of medications would be needed to accurately describe the risk of SIs in RA.

Table 1. Mean (SD) baseline characteristics of all RA and NIRD patients and by serious infections

All

Serious Infections

RA

NIRD

P-value

RA

NIRD

P-value

N

20,361

6,176

1,643

281

Age, yrs

58.2 (13.7)

62.8 (13.4)

<0.001

66.6 (12.0)

71.7 (11.9)

<0.001

Male, %

20.3

19.6

0.223

25.1

22.1

0.279

White, %

94.3

96.6

<0.001

94.6

95.7

0.449

BMI, kg/m2

28.9 (7.1)

29.4 (7.4)

<0.001

28.4 (7.5)

30.5 (8.4)

<0.001

Urban vs Rural, %

26.9

23.9

<0.001

32.3

25.2

0.018

Education, yrs

13.6 (2.4)

13.6 (2.4)

0.210

13.3 (2.3)

13.7 (2.3)

<0.001

Smoking History, %

41.5

34.9

<0.001

50.6

40.6

0.002

Disease duration, yrs

14.1 (12.5)

15.6 (13.5)

<0.001

19.7 (12.8)

21.9 (15.1)

0.010

Comorbidity index (0-9)

1.8 (1.6)

1.9 (1.6)

<0.001

2.5 (1.8)

2.6 (1.6)

0.650

HAQ (0-3)

1.1 (0.7)

1.1 (0.7)

0.300

1.3 (0.7)

1.2 (0.7)

<0.001

Pain (0-10)

4.2 (2.9)

4.2 (2.9)

0.900

4.5 (2.8)

4.7 (2.9)

0.260

Patient global (0-10)

3.8 (2.6)

3.8 (2.5)

0.940

4.3 (2.5)

4.1 (2.5)

0.450

Diabetes, %

8.6

8.9

0.520

13.9

17.7

0.094

Glucocorticoid use, %

28.3

4.43

<0.001

47.4

9.3

<0.001

Table 2. Incidence Rate Ratio (IRR) and Multivariable Hazard Ratios (HR) (95%CI) of serious infections by Etiology location

Infection

IRR first Infection

Multivariable HR first infection*

IRR recurrent Infection

Multivariable HR recurrent infection*

All infections

1.5 (1.3-1.7)

1.3 (1.2-1.5)

1.5 (1.4-1.7)

1.3 (1.2-1.5)

Opportunistic infections

3.0 (1.4-7.7)

1.9 (0.8-4.2)

3.3 (1.5-8.4)

1.9 (0.9-4.3)

Herpes zoster

2.2 (0.9-6.2)

1.8 (0.7-4.4)

2.4 (1.0-6.8)

1.9 (0.8-4.7)

Bacterial infections

1.6 (1.3-2.0)

1.4 (1.2-1.8)

1.6 (1.4-1.9)

1.4 (1.1-1.6)

Viral infections

1.5 (0.9-2.6)

1.3 (0.7-2.2)

1.5 (0.9-2.5)

1.2 (0.7-2.0)

Fungal infections

5.1 (1.3-43.3)

3.0 (0.7- 2.9)

5.4 (1.4-46.3)

2.9 (0.7-12.6)

Unknown cause

1.4 (1.2-1.7)

1.3 (1.1-1.5)

1.4 (1.2-1.7)

1.3 (1.1-1.5)

Respiratory

1.4 (1.2-1.7)

1.4 (1.1-1.6)

1.5 (1.3-1.7)

1.3 (1.1-1.6)

CNS

1.4 (0.4-7.5)

1.3 (0.4-5.0)

1.5 (0.4-7.9)

1.3 (0.4-4.8)

Abdominal

2.0 (1.0-4.3)

1.4 (0.7-2.8)

1.9 (1.0-3.9)

1.3 (0.7-2.6)

Urinary

0.8 (0.4-1.5)

0.7 (0.4-1.3)

0.9 (0.5-1.6)

0.7 (0.4-1.3)

Bloodstream infections including sepsis

1.8 (1.3-2.5)

1.6 (1.1-2.2)

1.8 (1.4-2.5)

1.6 (1.2-2.2)

Skin, bone and joint infections

1.5 (1.2-1.9)

1.3 (1.0-1.7)

1.5 (1.2-1.8)

1.3 (1.0-1.6)

Unknown type

2.6 (1.2-6.2)

1.8 (0.8-3.8)

2.7 (1.3-6.6)

1.8 (0.9-3.9)

*Multivariable Cox proportional hazard model adjusted for age, sex, race, HAQ, pain scale, rheumatic diseases comorbidity index, education level, residency (urban vs rural), glucocorticoid use, prior serious infections and smoking status


Disclosure: B. Y. Mehta, None; S. Pedro, None; G. Ozen, None; K. Michaud, None.

To cite this abstract in AMA style:

Mehta BY, Pedro S, Ozen G, Michaud K. Serious Infection Risk in Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Rheumatic Diseases: A US National Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/serious-infection-risk-in-patients-with-rheumatoid-arthritis-compared-to-patients-with-non-inflammatory-rheumatic-diseases-a-us-national-cohort-study/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serious-infection-risk-in-patients-with-rheumatoid-arthritis-compared-to-patients-with-non-inflammatory-rheumatic-diseases-a-us-national-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences